Pandemic as Teacher — Forcing Clinicians to Inhabit the Experience of Serious Illness | NEJM
Perspective from The New England Journal of Medicine — Pandemic as Teacher — Forcing Clinicians to Inhabit the Experience of Serious Illness
Related Articles
Breastfeeding After Hormone Receptor–Positive Breast Cancer: Results From the POSITIVE Trial
PURPOSEWe investigated breastfeeding patterns, behaviors, and association with breast cancer (BC) outcomes in women with early hormone receptor–positive (HR+) BC who had a live birth…
Long-Term Outcomes After Guideline-Recommended Treatment of Men With Prostate Cancer – PubMed
Men with nonmetastatic prostate cancer who received primary treatment according to current guidelines were up to 6 times more likely to die of other causes…
Breastfeeding After Hormone Receptor–Positive Breast Cancer: Results From the POSITIVE Trial
PURPOSEWe investigated breastfeeding patterns, behaviors, and association with breast cancer (BC) outcomes in women with early hormone receptor–positive (HR+) BC who had a live birth…
Long-Term Outcomes After Guideline-Recommended Treatment of Men With Prostate Cancer – PubMed
Men with nonmetastatic prostate cancer who received primary treatment according to current guidelines were up to 6 times more likely to die of other causes…
Breastfeeding after breast cancer in young BRCA carriers
AbstractBackground. We investigated safety of breastfeeding after breast cancer in patients carrying germline BRCA pathogenic or likely pathogenic variants
Breastfeeding after breast cancer in young BRCA carriers
AbstractBackground. We investigated safety of breastfeeding after breast cancer in patients carrying germline BRCA pathogenic or likely pathogenic variants
The OncoAlert Newsletter
The Latest in Oncology delivered weekly to your inbox, a simple click and you are set to go!
Zongertinib in Previously Treated HER2-Mutant Non–Small-Cell Lung Cancer | NEJM
Innovative oral targeted therapies are warranted for patients with human epidermal growth factor receptor 2 (HER2)–mutant non–small-cell lung cancer (NSCLC). Zongertinib is an oral, irreversible,…
Welcome! You are invited to join a webinar: [Live, Free Webinar] – From trials to practice: Applying the latest evidence in HER2+ metastatic breast cancer care. After registering, you will receive a confirmation email about joining the webinar.
Join this webinar on Thursday 26 June 2025, 19:00-20:00 CEST, where Elisa Agostinetto, Nicolò Matteo Luca Battisti, Fatima Cardoso and Véronique Diéras will discuss the…
MEDTALK | MEDSIR
Lung cancer is the second most common cancer and the leading cause of cancer-related deaths globally. Despite advancements, over 60% of patients are diagnosed at…